Company / PP&E (Net)
Moderna PP&E (Net) History
FY2017-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$2.0B
FY2022
5-year range
$1.2B / $2.0B
FY2018-FY2022
Trend
+62.6%
vs FY2021
Sector context
#14 of 193
Health Care
What the data says
Among 193 Health Care companies, Moderna is in the top 7% for pp&e (net). Improved from $209M to $2.0B over the past 3 years.
Based on SEC 10-K filings.
$2.0B in FY2022 with a 5-year CAGR of +70.8%. Top quartile in the Health Care sector.
Improved from $209M to $2.0B over the past 3 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +112.8%
- 5-Year CAGR
- +70.8%
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 193This company $2.0B Sector average $777.6M
▼
+159.5% above sector average
Key checks
Key Insights
- 5-year CAGR of +70.8%, indicating consistent growth.
- In FY2022, pp&e (net) increased 62.6% year-over-year.
- Ranks #14 out of 193 companies in the Health Care sector.
- Lowest pp&e (net) in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 1.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $2.0B | +62.6% |
| FY2021 | $1.2B | - |
| FY2020 | - | - |
| FY2019 | $209.5M | -1.2% |
| FY2018 | $212.0M | +52.5% |
| FY2017 | $139.0M | - |
| FY2016 | - | - |
As of FY2022 · SEC 10-K · Updated Jun 30, 2026